Crossmark

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Crossref DOI link: https://doi.org/10.1186/s13045-016-0338-2

Published Online: 2016-10-12

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Xuejiao

Chong, Yulong

Tu, Yiming

Liu, Ning

Yue, Chenglong

Qi, Zhenglei

Liu, Huize

Yao, Yao

Liu, Hongmei

Gao, Shangfeng

Niu, Mingshan

Yu, Rutong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81402074)

National Natural Science Foundation of China (81400167)

National Natural Science Foundation of China (81670142)

Natural Science Foundation of Jiangsu Province (CN) (BK20140227)

Natural Science Foundation of Jiangsu province (BK20140224)